Andere Kunden interessierten sich auch für
![Postoperative tumor recurrence in primary bronchopulmonary cancer]( "Postoperative tumor recurrence in primary bronchopulmonary cancer")
Postoperative tumor recurrence in primary bronchopulmonary cancer36,99 €![Superior Cave Syndrome and Primary Bronchopulmonary Cancer]( "Superior Cave Syndrome and Primary Bronchopulmonary Cancer")
Superior Cave Syndrome and Primary Bronchopulmonary Cancer29,99 €![Bronchopulmonary cancer in young people]( "Bronchopulmonary cancer in young people")
Bronchopulmonary cancer in young people29,99 €![Contribution of PET CT to 18 F FDG in bronchopulmonary cancer]( "Contribution of PET CT to 18 F FDG in bronchopulmonary cancer")
Contribution of PET CT to 18 F FDG in bronchopulmonary cancer26,99 €![Bronchopulmonary dysplasia]( "Bronchopulmonary dysplasia")
Bronchopulmonary dysplasia29,99 €![Particularities of bronchopulmonary cancer in women]( "Particularities of bronchopulmonary cancer in women")
Particularities of bronchopulmonary cancer in women23,99 €![Bronchopulmonary cancers]( "Bronchopulmonary cancers")
Bronchopulmonary cancers39,99 €
Introduction: Primary bronchopulmonary cancer represents the leading cause of cancer mortality in men worldwide. Objective: To evaluate the prognosis of patients with locally advanced and metastatic non-small cell lung carcinoma (NSCLC) and to determine prognostic factors at these stages. Methods: Retrospective study including 140 cases of locally advanced and metastatic NSCLC diagnosed in our department between 2003 and 2013. Results: The mean age was 61±10 years with a clear male predominance. The cancer was stage IIIA in 14%, IIIB in 27% and IV in 59%. Survival at 6 months and 1 year was 50-74% and 9-25%, respectively. Survival was significantly longer in patients with stage III cancer, a performance status (PS) of 0 to 1, comorbidities, prolonged time to positive diagnosis, short treatment time, and who received specific antitumor therapy. Conclusion: Prognostic factors for advanced NSCLC are PS, stage, comorbidities, time to management, and specific antitumor therapy.